price
CA
NASDAQ · CAI
Caris Life Sciences, Inc.
Healthcare · Biotechnology
$26.27
Up+$1.69 (+6.88%)
Updated Aug 24, 2026, 1:32 AM
SID Score
6.4/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.49B
- P/E ratio
- -34.61
- Dividend yield
- 0.00%
- 52-week range
- $14.19 – $29.32
- Volume
- 6.39M
- Avg. volume
- 1.42M
Price performance
CAI price history
1M range · 20 trading sessions · Daily adjusted prices
CAI closed at $26.27 after 20 trading sessions, up 68.07% for the selected period.
- Last close
- $26.27
- Period change
- +68.07%
- Period low
- $15.59
- Period high
- $26.27
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $24.73 | $26.60 | $24.32 | $26.27 | 6.39M |
| Aug 20, 2026 | $22.59 | $24.765 | $22.59 | $24.58 | 6.03M |
| Aug 19, 2026 | $21.92 | $22.94 | $21.92 | $22.76 | 6.56M |
| Aug 18, 2026 | $21.31 | $21.64 | $20.78 | $20.97 | 3.6M |
| Aug 17, 2026 | $22.00 | $22.19 | $21.52 | $21.63 | 2.77M |
| Aug 14, 2026 | $22.26 | $22.43 | $21.445 | $21.80 | 3.87M |
| Aug 13, 2026 | $22.84 | $23.12 | $22.14 | $22.18 | 2.97M |
| Aug 12, 2026 | $22.90 | $22.965 | $21.99 | $22.26 | 4.02M |
| Aug 11, 2026 | $23.39 | $23.66 | $22.99 | $23.14 | 6.04M |
| Aug 10, 2026 | $22.68 | $23.44 | $22.68 | $23.40 | 5.91M |
| Aug 7, 2026 | $20.695 | $22.77 | $20.1201 | $22.74 | 9.4M |
| Aug 6, 2026 | $19.00 | $20.11 | $17.945 | $20.00 | 11.27M |
| Aug 5, 2026 | $16.03 | $16.54 | $15.9616 | $16.45 | 6.77M |
| Aug 4, 2026 | $16.26 | $16.55 | $15.91 | $16.10 | 4.84M |
| Aug 3, 2026 | $15.92 | $16.59 | $15.835 | $16.32 | 4.9M |
| Jul 31, 2026 | $16.05 | $16.14 | $15.23 | $15.67 | 3.51M |
| Jul 30, 2026 | $15.58 | $16.17 | $15.46 | $16.09 | 4.54M |
| Jul 29, 2026 | $15.43 | $16.00 | $15.26 | $15.59 | 5.62M |
| Jul 28, 2026 | $15.74 | $16.03 | $15.41 | $15.59 | 3.62M |
| Jul 27, 2026 | $15.69 | $16.02 | $15.46 | $15.63 | 3.45M |
Latest CAI news
The latest Smart Investors Daily articles mentioning CAI.
Stock researchCompany · Overview
Loading stock research…